Effect of BRCA2 mutation on familial breast cancer survival: A systematic review and meta-analysis.
Reports of BRCA2 genetic mutations on the prognosis of familial breast cancer (BC) patients have been contradictory. True difference in survival, if it exists, would have important implications for genetic counseling and in treatment of hereditary BC. The purpose of this study was to compare overall survival rate (OSR) among BRCA2 mutation carriers, non-carriers and sporadic BC patients. We searched the PUBMED and EMBASE databases and retrieved 4529 articles using keywords that included breast cancer, BRCA, prognosis and survival. Nine articles were selected for systematic review and among them 6 were included in our meta-analysis. We used the fixed and random effect models to calculate the summary odds ratio (OR) and corresponding 95% confidence interval (CI). BRCA2 mutation carriers had significantly higher long-term OSR than non-carriers (OR=0.69 [95% CI=0.5-0.95]), while both short-term and long-term OSR of BRCA2 mutation carriers did not differ from those of patients with sporadic disease (OR=1.11 [95% CI=0.74-1.65]; 0.85 [95% CI=0.38-1.94], respectively). For BC-specific survival rate (BCSSR), BRCA2 mutation carriers had a similar BCSSR to the non-carriers (OR=0.61 [95% CI=0.28-1.34]). There was no significant difference in disease-free survival (DFS) between BRCA2 mutation carriers and patients with sporadic disease. Our results suggest that BRCA2 mutation increases long-term OSR in hereditary BC, which reminds us a new prospect of management of the disease.
Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, 430079, China.
Jun
J
Shao
Cancer Biology Research Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Jie
J
Yang
Cancer Biology Research Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Jun-Nai
JN
Wang
Cancer Biology Research Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Long
L
Qiao
Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, 430079, China.
Wei
W
Fan
Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, 430079, China. qlgao@tjh.tjmu.edu.cn.
Qing-Lei
QL
Gao
Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, 430079, China. 37865915@qq.com.
Yao-Jun
YJ
Feng
D024682:BRCA2 Protein / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D005260:Female; D015870:Gene Expression; D005817:Genetic Counseling; D020022:Genetic Predisposition to Disease; D006801:Humans; D009154:Mutation; D016017:Odds Ratio; D011379:Prognosis; D016019:Survival Analysis
D024682:BRCA2 Protein; C551750:BRCA2 protein, human
BRCA2 gene mutation; familiar breast cancer; overall survival rate